07:00 , Oct 13, 2014 |  BC Week In Review  |  Company News

Genetic Technologies sales and marketing update

Genetic Technologies' Phenogen Sciences Inc. subsidiary launched BREVAGenplus in the U.S. to assess a women's risk of developing sporadic or non-hereditary breast cancer. According to Genetic Technologies, the test is designed for Caucasian, Hispanic and...
07:00 , Sep 29, 2014 |  BC Week In Review  |  Company News

Genetic Technologies diagnostic news

Genetic Technologies announced plans to restructure and realign activities to focus on the U.S. molecular diagnostics market and commercialization of its BREVAGen test. Genetic Technologies markets BREVAGen to determine an individual's risk of developing...
07:00 , Mar 17, 2014 |  BC Week In Review  |  Clinical News

BREVAGen diagnostic data

Data from Caucasian women with an intermediate 5-year risk of developing breast cancer in a U.S. cost-effectiveness study showed that the incremental cost-effectiveness ratio (ICER) for using the BREVAGen test plus a clinical risk assessment...
08:00 , Feb 17, 2014 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 2/14 cls Depomed Inc. (NASDAQ:DEPO) Roth Capital Partners Scott Henry Downgrade Neutral (from...
07:00 , Sep 9, 2013 |  BC Week In Review  |  Clinical News

BREVAGen regulatory update

Genetic Technologies said the New York State Department of Health issued a clinical laboratory permit to allow the company to perform its BREVAGen genetic test to determine an individual's risk of developing non-familial breast cancer....
07:00 , Aug 13, 2012 |  BC Week In Review  |  Clinical News

BREVAGen regulatory update

Genetic Technologies received CE Mark approval for its BREVAGen genetic test to determine an individual's risk of developing non-familial breast cancer. The breast cancer stratification test combines a DNA-based profile of breast cancer-associated SNPs with...
07:00 , Jun 27, 2011 |  BC Week In Review  |  Company News

Genetic Technologies sales and marketing update

Genetic Technologies' Phenogen Sciences Inc. subsidiary launched the BREVAGen genetic test in the U.S. to determine a patient's lifetime and five-year risk for developing non-familial breast cancer. The breast cancer stratification test combines a...
07:00 , Apr 26, 2010 |  BC Week In Review  |  Company News

Genetic Technologies, Perlegen deal

Genetic Technologies said it acquired essentially all of Perlegen's assets, including all rights related to Perlegen's BREVAGen breast cancer stratification test and a suite of international patents valid until 2022 related to genomic mapping...
07:00 , Sep 28, 2009 |  BC Week In Review  |  Company News

Perlegen sales and marketing update

Perlegen launched its BREVAGen breast cancer stratification test in selected U.S. markets. The test combines a DNA-based profile of breast cancer-associated SNPs with the patient's clinical history to determine the patient's lifetime and five-year...